Home > Gastroenterology > ECCO 2021 > Biologics Updates > Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Presented By
Dr Peter Irving, Guy’s and St. Thomas’ Hospital, UK
Conference
ECCO 2021
Trial
SEAVUE
Ustekinumab and adalimumab both showed high efficacy in biologic-naïve patients with moderate-to-severe Crohn’s disease (CD). No significant difference in clinical remission rate was observed between the two therapies at 52 weeks of follow-up. The multicentre, randomised, blinded SEAVUE study was the first trial comparing these two biologics head-to-head in a population of CD patients. Head-to-head studies are needed to make informed treatment decisions. In the SEAVUE study (NCT03464136), biologic-naïve moderate-to-severe CD patients (n=386) were randomised to ustekinumab, an IL-12/23(p40) antagonist, or adalimumab, a TNF antagonist. Safety and efficacy of both therapies was assessed. Patients in the ustekinumab arm received 6 mg/kg ustekinumab, intravenously injected, followed by a subcutaneous dose of 90 mg every 8 weeks. Patients in the adalimumab arm received 4 doses of 40 m...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on